FEATURED, Genetics, Genomics, Research
STUDY SUGGESTS BENEFIT OF DRUG TARGETING PIK3CA-MUTATED BREAST CANCER
Located on chromosome 3, PIK3CA is mutated in approximately 40% of patients with hormone receptor (HR) positive, Her2 negative breast cancer. Standard therapy f...
FEATURED, Genetics, Genomics, News, Genetic Engineering, Germline
Concerns Rise Following CRISPR Revelation from China
International moratorium called for by CRISPR scientists
FEATURED, Genetics, Genomics, Genetic Testing
Mutation Predicts Survival but only in ER-positive Patients
IMPLICATIONS OF TP53 SOMATIC MUTATIONS ARE MOLECULAR SUBTYPE SPECIFIC The somatic mutation TP53—in addition to being critical in maintaining the stability of th...
FEATURED, Genomics, Industry, Risk Assessment, Genetic Testing
Cyber Monday for Genomic Testing - Whole Genome Sequencing for $199
Ever think you would hear about a holiday special for genomic testing? Veritas Genetics is offering this $999 whole genome testing for the first 1000 people who...
What was the first targeted therapy for breast cancer?
A BRIEF HISTORY OF HER2/NEU Trastuzumab was not the first targeted therapy for breast cancer. It’s likely that the first targeted therapy in modern times was o...
FEATURED, Genomics, News, Radiation, Regional Management, Risk Assessment
Influence of the subtype on local recurrence risk of breast cancer with or without radiotherapy
Breast Cancer Subtype May Be Predictive of Ipsilateral Breast Tumor Recurrence Studies have shown that certain intrinsic subtypes of breast cancer are associate...
FEATURED, Genomics, News, Risk Assessment, Histology
Standard Light Microscopy Illuminates a Molecular Mystery
Why do triple negative breast cancers in BRCA-1 patients have a better prognosis?
Chemotherapy May Be Safely Withheld for Breast Cancer Patients with 21-gene Recurrence Scores Under 26
TAILORx trial presented at ASCO and simultaneously published in NEJM (June 3, 2018). Joseph Sparano M.D. presented the long awaited results of the TAILORx st...
